Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, will retire at the end of 2025 after a 30-year career with the company. Her leadership has spanned multiple areas, including cancer, brain health, and infectious diseases. Eli Lilly is currently searching for her successor. Under Anne’s leadership, Lilly has developed new treatments for brain diseases, pain, addiction, and mental health. She helped speed up the process of creating and approving new medicines, making them available to patients faster. One of her biggest achievements was leading the global launch of Lilly’s first Alzheimer’s disease treatment. Before that, she led Lilly’s cancer division and played a key role in developing new cancer treatments and acquiring Loxo Oncology. Anne has over 25 years of experience in the pharmaceutical industry and has been recognized for her support of women in the workplace. She previously worked in research and development at Lilly and served as Chief Operating Officer at Tigris Pharmaceuticals. She holds a degree in Industrial and Operations Engineering from the University of Michigan. David Ricks, Lilly’s CEO, praised Anne for her contributions, saying, ‘Anne led the global launch of our first-ever Alzheimer’s treatment. She was also instrumental in growing our cancer treatment portfolio and acquiring Loxo Oncology.’ Recently, Lilly announced promising long-term results for Kisunla, an Alzheimer’s drug, which could lead to shorter treatment durations. Ricks thanked Anne for her dedication, stating, ‘On behalf of our Board, leadership team, and thousands of employees, I would like to thank Anne for her service to our company and our mission.’